These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9010685)

  • 1. The differentiation of propafenone from other class Ic agents, focusing on the effect on ventricular response rate attributable to its beta-blocking action.
    Faber TS; Camm AJ
    Eur J Clin Pharmacol; 1996; 51(3-4):199-208. PubMed ID: 9010685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-adrenoceptor blocking activity of diprafenone in anesthetized dogs: comparison with propafenone and propranolol.
    Greenberg S; Cantor E; Paul J
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):444-53. PubMed ID: 2476625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the beta-adrenoceptor blocking activity of the Class Ic antiarrhythmic drug diprafenone in man.
    Wagner F; Jähnchen E; Trenk D
    Eur J Clin Pharmacol; 1989; 36(6):579-82. PubMed ID: 2570700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propafenone shows class Ic and class II antiarrhythmic effects.
    Stoschitzky K; Stoschitzky G; Lercher P; Brussee H; Lamprecht G; Lindner W
    Europace; 2016 Apr; 18(4):568-71. PubMed ID: 26056191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
    Bryson HM; Palmer KJ; Langtry HD; Fitton A
    Drugs; 1993 Jan; 45(1):85-130. PubMed ID: 7680987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
    Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
    Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the beta-adrenoceptor blocking property of diprafenone in rats: stereoselective interaction, subtype specificity, and sensitization.
    Nanoff C; Schütz W
    J Cardiovasc Pharmacol; 1991 Dec; 18(6):837-42. PubMed ID: 1725895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.
    Groschner K; Lindner W; Schnedl H; Kukovetz WR
    Br J Pharmacol; 1991 Mar; 102(3):669-74. PubMed ID: 1364837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-adrenergic stimulation modulates the sodium current block by propafenone in rat ventricular myocardium.
    Maier SK; Kirstein M
    J Electrocardiol; 2002 Oct; 35(4):343-9. PubMed ID: 12395362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative frequency-dependent effects of three class Ic agents, Org 7797, flecainide, and propafenone, on ventricular action potential duration.
    Winslow E; Campbell JK
    J Cardiovasc Pharmacol; 1991 Dec; 18(6):911-7. PubMed ID: 1725906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
    Galimberti ES; Knollmann BC
    J Mol Cell Cardiol; 2011 Nov; 51(5):760-8. PubMed ID: 21798265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes.
    Slawsky MT; Castle NA
    J Pharmacol Exp Ther; 1994 Apr; 269(1):66-74. PubMed ID: 8169853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology and beta-blocking efficacy of propafenone.
    Barbey JT
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S41-3. PubMed ID: 1723117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination.
    Biffi M; Boriani G; Bronzetti G; Capucci A; Branzi A; Magnani B
    Heart; 1999 Aug; 82(2):176-82. PubMed ID: 10409531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multiple modes of action of propafenone.
    Dukes ID; Vaughan Williams EM
    Eur Heart J; 1984 Feb; 5(2):115-25. PubMed ID: 6144546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propafenone: an effective agent for the management of supraventricular arrhythmias.
    Grant AO
    J Cardiovasc Electrophysiol; 1996 Apr; 7(4):353-64. PubMed ID: 8777484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1987 Dec; 34(6):617-47. PubMed ID: 3322781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies.
    Stoschitzky K; Klein W; Stark G; Stark U; Zernig G; Graziadei I; Lindner W
    Clin Pharmacol Ther; 1990 Jun; 47(6):740-6. PubMed ID: 2162749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.